Academic literature on the topic 'DRD2 receptors polymorphisms'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'DRD2 receptors polymorphisms.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "DRD2 receptors polymorphisms"
1
Eisenberg, Dan T. A., Benjamin Campbell, James MacKillop, et al. "Polymorphisms in the Dopamine D4 and D2 Receptor Genes and Reproductive and Sexual Behaviors." Evolutionary Psychology 5, no. 4 (2007): 147470490700500. http://dx.doi.org/10.1177/147470490700500402.
Full textAbstract:
Human reproductive and sexual behaviors are heritable and may represent integral life history traits that are likely partially subserved by the dopamine system. Two dopamine receptor polymorphisms, DRD4 48bp VNTR and DRD2 TaqI A, were examined in relation to the Sexual-Orientation Inventory (SOI), age at first sexual intercourse, desired age of marriage, and desired age to have children in 195 (45% male) individuals from a general student population. As DRD4 7R alleles have been associated with migratory behavior, we also examined whether those with more 7R alleles had a greater frequency of multi-racial ancestries. Minor alleles of both polymorphisms (7R and A1 respectively) are believed to decrease the function of their respective receptors. Individuals with DRD4 7R alleles were more likely to have had sexual intercourse and to desire children earlier in life. In addition, DRD4 7R+ individuals were more likely to report multi-racial ancestries. Individuals with DRD2 A1 alleles were more likely to not want children and not want to marry. These results suggest that polymorphisms in the DRD4 and DRD2 genes are meaningfully associated with variation in reproductive and sexual behaviors. These results are provisionally interpreted as consistent with other findings suggesting that DRD4 7R and DRD2 A1 alleles are adaptive for lower offspring investment strategies in dynamic social environments.
2
Syamsuddin, Saidah, Irawan Yusuf, Jayalangkara Tanra, and Irfan Idris. "The Polymorphisms of DRD2 141-C Ins/Del Receptor Influenced the Treatment Responses of Schizophrenia Patients." Neuropsychiatry 9, no. 5 (2019): 4. https://doi.org/10.5281/zenodo.13594392.
Full textAbstract:
Polymorphisms of DRD2 receptors lead to vary in the treatment responses of schizophrenia patients. Objectives: This study carried out to know the association of polymorphisms of DRD2 141-C Del/Ins receptors to the doses needed of antipsychotic drug, length of hospital stay, and improvement of symptoms of schizophrenia patients. Methods: The 208 of schizophrenia patients recruited in this study, was hospitalized and have given haloperidol (first generation of antipsychotic drug) then the treatment responses were evaluated by CGI score. The genotyping of the blood performed for DRD2 receptors polymorphisms. Results: This study showed that DD genotype needed higher doses of antipsychotic drugs (p<0,05), have longer hospital stay (p><0,05), and have a minimum improvement of symptoms (p><0,05). Conclusion: It was concluded that polymorphisms of DRD2 141-C Del/Ins receptors influenced the treatment responses and should be considered when treating schizophrenia patients with haloperidol.> <0,05), have longer hospital stay (p<0,05), and have a minimum improvement of symptoms (p<0,05) Conclusion: It was concluded that polymorphisms of DRD2 141-C Del/Ins receptors influenced the treatment responses and should be considered when treating schizophrenia patients with haloperidol.
3
Vaiman, Elena E., Natalia A. Shnayder, Maxim A. Novitsky, et al. "Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients." Biomedicines 9, no. 8 (2021): 879. http://dx.doi.org/10.3390/biomedicines9080879.
Full textAbstract:
(1) Introduction: Extrapyramidal disorders form the so-called extrapyramidal syndrome (EPS), which is characterized by the occurrence of motor disorders as a result of damage to the basal ganglia and the subcortical-thalamic connections. Often, this syndrome develops while taking medications, in particular antipsychotics (APs). (2) Purpose: To review studies of candidate genes encoding dopamine receptors as genetic predictors of development of AP-induced parkinsonism (AIP) and AP-induced tardive dyskinesia (AITD) in patients with schizophrenia. (3) Materials and Methods: A search was carried out for publications of PubMed, Web of Science, Springer, and e-Library databases by keywords and their combinations over the last 10 years. In addition, the review includes earlier publications of historical interest. Despite extensive searches of these commonly used databases and search terms, it cannot be ruled out that some publications were possibly missed. (4) Results: The review considers candidate genes encoding dopamine receptors involved in pharmacodynamics, including genes DRD1, DRD2, DRD3, and DRD4. We analyzed 18 genome-wide studies examining 37 genetic variations, including single nucleotide variants (SNVs)/polymorphisms of four candidate genes involved in the development of AIP and AITD in patients with schizophrenia. Among such a set of obtained results, only 14 positive associations were revealed: rs1799732 (141CIns/Del), rs1800497 (C/T), rs6275 (C/T), rs6275 (C/T) DRD2; rs167771 (G/A) DRD3 with AIP and rs4532 (A/G) DRD1, rs6277 (C/T), rs6275 (C/T), rs1800497 (C/T), rs1079597 (A/G), rs1799732 (141CIns/Del), rs1045280 (C/G) DRD2, rs6280 (C/T), rs905568 (C/G) DRD3 with AITD. However, at present, it should be recognized that there is no final or unique decision on the leading role of any particular SNVs/polymorphisms in the development of AIP and AITD. (5) Conclusion: Disclosure of genetic predictors of the development of AIP and AITD, as the most common neurological adverse drug reactions (ADRs) in the treatment of patients with psychiatric disorders, may provide a key to the development of a strategy for personalized prevention and treatment of the considered complication of AP therapy for schizophrenia in real clinical practice.
4
Boiko, A. S., I. V. Pozhidaev, O. Z. Paderina, and A. V. Semke. "Genes of dopamine receptors and transporter in patients with schizophrenia: associations with the clinical characteristics of the disorder." V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY, no. 4-1 (December 9, 2019): 93–94. http://dx.doi.org/10.31363/2313-7053-2019-4-1-93-94.
Full textAbstract:
Genotyping of 28 polymorphisms of 5 dopamine receptor genes and 12 polymorphisms of dopamine transporter gene was performed in 475 schizophrenia patients and 135 healthy individuals. Associations of several polymorphisms of the DRD2, DRD3 and SLC6A3 genes were identified with leading symptoms and late debut of schizophrenia.
5
Paderina, Diana Z., Anastasiia S. Boiko, Ivan V. Pozhidaev, et al. "The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia." Genes 13, no. 8 (2022): 1312. http://dx.doi.org/10.3390/genes13081312.
Full textAbstract:
Background: Metabolic syndrome is widespread in patients with schizophrenia receiving long-term antipsychotic therapy. Dopamine D2 receptors play an important role in mediating both the therapeutic actions of antipsychotics and their side effects. The present study examined the association of two polymorphisms of the DRD2 gene with metabolic syndrome in patients with schizophrenia. Methods: We examined 517 patients from several regions of Siberia (Russia) with a clinical diagnosis of schizophrenia. Genotyping of two single nucleotide polymorphisms rs1799732 and rs4436578 of the dopamine D2 receptor gene (DRD2) was performed in a population of 471 patients. The results were analyzed using chi-square tests. Results: Functional polymorphism rs1799732 of the DRD2 gene is associated with drug-induced metabolic syndrome in women with schizophrenia. Conclusions: Our results show that the DRD2 gene may be involved in the pathogenesis of metabolic disorders in patients with schizophrenia. Further analysis of possible genetic markers will allow for personalized treatment with minimal side effects and optimal efficacy. This which seems relevant in light of the recent focus on improving the quality of life and ensuring a high level of social adaptation of patients with schizophrenia.
6
Szczerbal, I., J. Nowacka-Woszuk, M. Racka, et al. "Cytogenetic mapping and STR polymorphism of two candidate genes (<i>DRD2</i> and <i>HTR1D</i>) for behaviour traits in four canids (short communication)." Archives Animal Breeding 50, no. 4 (2007): 412–17. http://dx.doi.org/10.5194/aab-50-412-2007.
Full textAbstract:
Abstract. The dopamine D2 receptor (DRD2) and serotonin receptors 1D (HTR1D) are candidate genes for behavioural traits. In the present study, we show chromosomal location and polymorphism of these genes in four species from the family Canidae: dog (CFA), red fox (VVU), arctic fox (ALA) and the Chinese raccoon dog (NPP). Using fluorescence in situ hybridisation (FISH) the DRD2 gene was localized in the following chromosomes: CFA5q12-13, VVU12q21, ALA10q14 and NPP3q14 and the HTR1D gene was mapped to: CFA2q25, VVU2q22, ALA8q25 and NPP10q25. A microsatellite marker (TG)n in intron 3 of the DRD2 gene and (CA)n motif located in a 3’-flanking region of the HTR1D gene were polymorphic in all studied species. The obtained results can be helpful in further studies on effects of polymorphisms of these genes on behaviour traits in canids.
7
Park, Hae-Yeon, Hyun-Mi Oh, Tae-Woo Kim, et al. "Single Nucleotide Polymorphisms May Increase the Risk of Aspiration Pneumonia in Post-Stroke Patients with Dysphagia." Current Issues in Molecular Biology 44, no. 8 (2022): 3735–45. http://dx.doi.org/10.3390/cimb44080255.
Full textAbstract:
This study aimed to evaluate whether genetic polymorphism is associated with an increased risk of infection, specifically post-stroke aspiration pneumonia. Blood samples were obtained from a total of 206 post-stroke participants (males, n = 136; mean age, 63.8 years). Genotyping was performed for catechol-O-methyltransferase (rs4680, rs165599), dopamine receptors (DRD1; rs4532, DRD2; rs1800497, DRD3; rs6280), brain-derived neurotrophic factor (rs6265), apolipoprotein E (rs429358, rs7412), and the interleukin-1 receptor antagonist gene (rs4251961). The subjects were stratified into two groups, aged < 65 (young) and ≥ 65 (elderly). Functional parameters and swallowing outcomes were measured at enrollment and at 3 months post-onset. The primary outcome was the incidence of aspiration pneumonia. Analysis of the association between genetic polymorphisms and aspiration pneumonia history showed that a minor C rs429358 allele was associated with the occurrence of aspiration pneumonia in the young group, both in the additive and the dominant models (odds ratio: 4.53; 95% CI: 1.60–12.84, p = 0.004). In the multivariable analysis, the minor C rs429358 allele increased the risk of post-stroke aspiration pneumonia in young stroke patients by 5.35 (95% CI: 1.64–20.88). In contrast, no such association was observed in the elderly group. Apolipoprotein E polymorphism may affect the risk of post-stroke aspiration pneumonia.
8
Colzato, Lorenza S., Heleen A. Slagter, Mischa de Rover, and Bernhard Hommel. "Dopamine and the Management of Attentional Resources: Genetic Markers of Striatal D2 Dopamine Predict Individual Differences in the Attentional Blink." Journal of Cognitive Neuroscience 23, no. 11 (2011): 3576–85. http://dx.doi.org/10.1162/jocn_a_00049.
Full textAbstract:
The attentional blink (AB)—a deficit in reporting the second of two target stimuli presented in close succession in a rapid sequence of distracters—has been related to processing limitations in working memory. Given that dopamine (DA) plays a crucial role working memory, the present study tested whether individual differences in the size of the AB can be predicted by differences in genetic predisposition related to the efficiency of dopaminergic pathways. Polymorphisms related to mesocortical and nigrostriatal dopaminergic pathways were considered, as well as polymorphisms related to norepinephrine (NE), a transmitter system that has also been suspected to play a role in the AB. In a sample of 157 healthy adults, we studied the dependency of the individual magnitude of the AB and the C957T polymorphism at the DRD2 gene (associated with striatal DA/D2 receptors), the DARPP32 polymorphism (associated with striatal DA/D1), the COMT Val158Met polymorphism (associated with frontal DA), DBH444 g/a and DBH5′-ins/del polymorphisms (polymorphisms strongly correlated with DA beta hydroxylase, the enzyme catalyzing the DA–NE conversion) and NET T-182C (a polymorphism related to the NE transporter). DRD2 C957T T/T homozygotes showed a significantly smaller AB, whereas polymorphisms associated with frontal DA and NE were unrelated to performance. This outcome pattern suggests a crucial role of the nigrostriatal dopaminergic pathway and of nigrostriatal D2 receptors, in particular, in the management of attentional resources.
9
Blokhina ., Е. A., E. М. Krupitsky, А. O. Kibitov, et al. "Exploring genetic predictors of naltrexone treatment response in opioid use disorder." V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY, no. 4-1 (December 9, 2019): 61–64. http://dx.doi.org/10.31363/2313-7053-2019-4-1-61-64.
Full textAbstract:
Purpose: The present study was aimed to evaluate the effect of the opioid receptors genes and dopamine system genes polymorphisms on the treatment outcomes of opioid dependence with implantable and oral naltrexone in randomized double blinded double dummy placebo controlled clinical trial. Methods: 306 patients with opioid dependence were randomized in 3 treatment groups (102 ss in each). The first group received implantation of 1000 mg naltrexone every 2 months during the 6 months period + oral naltrexone placebo; the second group — placebo implant every 2 months + oral naltrexone (50mg/day), and the third group — placebo implant + oral naltrexone placebo. All enrolled participants provided blood sample at baseline for genetic analysis of polymorphisms in following genes: mu-opioid receptor (OPRM1), kappa-opioid receptor (OPRK1), catechol-O-methyltransferase (COMT), dopamine receptors types 2 (DRD2) and 4 (DRD4), dopamine-beta-hydroxylase, and dopamine transporter (DAT1). Results: Regardless of provided treatment several polymorphisms of tested genes were associated with high risk of relapse: allele L (2R) DRD4 120bp (p=0.05; OR(95% CI)=3.3(1.1-10.1) ); allele С DRD2 NcoI (р=0,051 OR(95% CI) = 2,86 (1,09 — 7,52); genotype 9.9 DAT VNTR40bp (р=0,04; RR(95% CI) = 1,4(1,3 — 1,5)); on the contrary variants of polymorphisms (СС+СТ)-(ТТ)) of genes (OPRK1- DRD2Ncol) increased the chance to complete the treatment program (р=0,004; OR(95% CI) = 7.4 (1.8 — 30.4)), Kaplan-Meier survival analysis, р=0,016). The probability of completing treatment program by carriers of all these above mentioned variants of polymorphisms (OPRK1DRD2Ncol) was higher for oral naltrexone group (p=0.016), lower for double placebo group (p=0.015), but did not influence treatment outcomes in naltrexone-implant group. Conclusion: Naltrexone-implant is an effective medication for treatment of opioid dependence and its effectiveness exceeds oral naltrexone and placebo. The study showed joint influence of opioid receptor genes and genes of dopaminergic system on the treatment outcomes of opioid dependence. Genetic analysis is useful for determining potential responders to naltrexone treatment of opioid dependence.
10
Ventriglio, A., A. Petito, A. Gentile, et al. "Pharmacodynamic targets of psychotic patients treated with a long-acting therapy." European Psychiatry 41, S1 (2017): S366—S367. http://dx.doi.org/10.1016/j.eurpsy.2017.02.370.
Full textAbstract:
IntroductionGiven the poor compliance of schizofrenic patients to antipsychotic therapies, are been developed drugs in long-acting formulation that for their pharmacokinetic ensures prolonged therapeutic activities. Currently, we consider that their efficacy depends on hereditary tracts, influencing both pharmacodynamic and pharmacokinetic parameters.ObjectiveInvestigate relationships between clinical efficacy and genetic polymorphims of long-acting drugs’ pharmacodynamic targets.MethodsSeventy-eight psychotic patients, treated with atypical long-acting antipsychotics (olanzapine pamoate, paliperidone palmitate, risperidon and aripiprazole), were examined. We carried out a blood sampling to evaluate dopaminergic DRD2 and glutamatergic GRM3 genetic receptors polymorphisms. PANSS and BPRS scales were used to assess clinical condition.ResultsRegarding the GRM3 genes, the study of rs2228595 and rs6465084 polymorphisms showed a prevalence of wild type genotypic frequency of 81.2% and 56.2%, respectively. The prevalence of the patients with mutated heterozygote genotype (rs6465084 polymorphisms) resulted high (40.6%). Considering rs1989796 e rs274622 polymorphisms, the sample showed a prevalence of mutated heterozygote genotype in the 53.1% e 45.3%, respectively, with a percentage of 43.7% of patients with a mutation in homozygosis. Considering the rs146812 polymorphism, the 53.1% of patients resulted with a wild type genotype. Finally, findings showed a prevalence of 56.2% for the mutated heterozygote genotype in the DRD2 rs6277 polymorphism. The genotypic categorization analysis demonstrated a significative association between the GRM3 rs274622 polymorphism and higher BPRS scores.ConclusionsThe relationship between rs274622 polymorphism and worse clinical conditions could indicate a major resistance to long-acting antipsychotics in patients with genotypic frequency CT (mutated heterozygosis) for this polymorphism.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Dissertations / Theses on the topic "DRD2 receptors polymorphisms"
1
FRoehlich, Tanya. "ADHD-related Executive Functions: Interactions of a DRD4 Polymorphism, Lead, and Sex." University of Cincinnati / OhioLINK, 2007. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1185465160.
Full text
2
Strobel, Alexander, Frank M. Spinath, Alois Angleitner, Rainer Riemann, and Klaus-Peter Lesch. "Lack of Association between Polymorphisms of the Dopamine D4 Receptor Gene and Personality." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-134660.
Full textAbstract:
Recent studies have suggested a role of two polymorphisms of the dopamine D4 receptor gene (DRD4 exon III and –521C/T) in the modulation of personality traits such as ‘novelty seeking’ or ‘extraversion’, which are supposed to be modulated by individual differences in dopaminergic function. However, several replication studies have not provided positive findings. The present study was performed to further investigate whether DRD4 exon III and –521C/T are associated with individual differences in personality. One hundred and fifteen healthy German volunteers completed the NEO-Five-Factor Inventory (NEO-FFI) and were genotyped for the two DRD4 polymorphisms. We found no association between DRD4exon III and –521C/T, respectively, and estimated novelty seeking, NEO-FFI extraversion or other personality factors. Our findings are in line with several earlier studies which have failed to replicate the initial association results. Hence, our data do not provide evidence for a role of DRD4 exon III and the –521C/T polymorphism in the modulation of novelty seeking and extraversion<br>Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
3
Strobel, Alexander, Frank M. Spinath, Alois Angleitner, Rainer Riemann, and Klaus-Peter Lesch. "Lack of Association between Polymorphisms of the Dopamine D4 Receptor Gene and Personality." Karger, 2003. https://tud.qucosa.de/id/qucosa%3A27586.
Full textAbstract:
Recent studies have suggested a role of two polymorphisms of the dopamine D4 receptor gene (DRD4 exon III and –521C/T) in the modulation of personality traits such as ‘novelty seeking’ or ‘extraversion’, which are supposed to be modulated by individual differences in dopaminergic function. However, several replication studies have not provided positive findings. The present study was performed to further investigate whether DRD4 exon III and –521C/T are associated with individual differences in personality. One hundred and fifteen healthy German volunteers completed the NEO-Five-Factor Inventory (NEO-FFI) and were genotyped for the two DRD4 polymorphisms. We found no association between DRD4exon III and –521C/T, respectively, and estimated novelty seeking, NEO-FFI extraversion or other personality factors. Our findings are in line with several earlier studies which have failed to replicate the initial association results. Hence, our data do not provide evidence for a role of DRD4 exon III and the –521C/T polymorphism in the modulation of novelty seeking and extraversion.<br>Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
4
Djivré, Ilan-Alan. "Cognitive testing and analysis of the dopamine receptor D4 (DRD4) exon III polymorphism and CSF metabolites in male African green monkeys (Chlorocebus aethiops)." Thesis, McGill University, 2006. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=99335.
Full textAbstract:
A sample of 100 male vervets was appraised with the Object Retrieval Task (ORT- a test of general cognitive ability) and Time-Restricted Arousal Induction Test (TRAIT- a response performance task based on ethological observations) and genotyped for a VNTR residing in exon III of the dopamine receptor 4 (DRD4) gene. A factor analysis of the combined measurements has revealed 3 factors, accounting for 70% of the variability. They were interpreted as cognitive ability (eigenvalue=4.3), cautiousness (eigenvalue=2.1) and impulsive responding (eigenvalue=1.3). No association was found between the DRD4 VNTR alleles and impulsive responding (F1,93 =0.082, p=0.775). The smallest and youngest within this sample of young adults have been found to display the most cautious behavior (p=0.002). The heaviest subjects displayed the most uninhibited response-style (p=0.045). And lastly, monkeys with cognitive difficulties had the highest CSF levels of the dopamine metabolite, HVA (p=0.017).<br>The ORT and TRAIT provide rapid screening measures of cognitive ability, cautiousness and impulsive-responding, but extensive validation of these measures with classical cognitive tests was beyond the scope of this project. The relationship between cognitive performance and resting levels of dopamine metabolites suggests that the battery may be useful in future studies of various psychopathological models in this species.
5
JANDOVÁ, Linda. "Možná asociace polymorfismů v genu pro dopaminový receptor D2 (\kur{DRD2}) s lidským chováním." Master's thesis, 2019. http://www.nusl.cz/ntk/nusl-394613.
Full textAbstract:
This study is focused on the dopamine D2 receptor and the linkage between TaqIA and - 141C Ins/Del polymorphisms in DRD2 gene and novelty seeking behaviour, as well as the linkage between Val158Met polymorphism in COMT gene and novelty seeking behaviour. Novelty seeking behaviour is characterized as a personality trait with a tendency to look for novel stimulation and extravagances at any cost of legal, physical and social risk to reward cues. DRD2 and COMT genes are associated with the function of dopamine, which is essential for motoric function and reward-motivated behaviour. Therefore, the aim of this study is to ascertain the potential linkage among the three studied polymorphisms and novelty seeking behaviour.
6
Abdulnour, Shahad. "Effect of Dopamine Receptor DRD2 and ANKK1 Polymorphisms on Dietary Compliance, Blood Pressure, and BMI in Type 2 Diabetic Patients." Thesis, 2010. http://hdl.handle.net/1807/25396.
Full textAbstract:
Reduction in dopamine receptor D2, has been associated with insufficient brain reward, food addiction, obesity, and type 2 diabetes (T2D). Our aim was to assess whether the genetic variability responsible for this reduction is associated with poor dietary compliance and life style habits in T2D patients. Genetic-analysis was done for 109 T2D individuals who completed a 24-week randomized clinical trial and were assigned to follow either a low-GI or a high-fibre diet. Polymorphisms of TaqIA and C957T were compared with physical and biochemical measures. Regardless of dietary treatments, individuals with the C957T-T allele and the TaqIA-A2 allele were significantly associated with blood pressure reduction. Carriers of the T allele significantly lowered their body mass index (BMI) over the 24-week trial. Our findings suggest that the presence of the TaqIA-A2 allele is associated with a decrease in blood pressure. The C957T-T allele was associated with decrease in pressure and body weight.
7
EGRIOVÁ, Simona. "Rizikové chování v závislosti na genu alela A1 pro dopaminový receptor D2." Master's thesis, 2019. http://www.nusl.cz/ntk/nusl-394873.
Full textAbstract:
The studies that have been published since 1990 which are dealing with the relationship of the genetic polymorphism of the dopamine D2 receptor gene (DRD2) in relation to alcoholism or other disorders or diseases have brought contradictory results. These results have led the author of this thesis to closely investigate the relationship between the genetic polymorphism of the A1 allele gene for DRD2 and hazardous alcohol consumption in the Czech Republic with a focus on the artistic area. A total of 29 participants (15 artists and 14 "non-artists") were involved in the study. The criterion for selecting the examined sample was the type of professional focus (artistic, non-artistic). A genetic analysis of blood (PCR-RFLP method) was used to determine the genotype. Only in the "non-artistic" group the presence of the genetic polymorphism of the A1 allele for DRD2 was found (a predisposition to a risk behavior in relation to alcohol). Additional parameters were found using EEG, an AUDIT test and a temperament questionnaire. A statistical analysis confirmed an association between the appearance of the A1 allele for DRD2 and a higher amplitude of the P300 component (p = 0.0000421). Statistically proven riskier alcohol consumption was found among introverted artists (n = 9) in the AUDIT test (p = 0.02298).
8
Da, Costa Laura Anne. "Genetic Modifiers of Caffeine Consumption and Risk of Myocardial Infarction." Thesis, 2011. http://hdl.handle.net/1807/29516.
Full textAbstract:
The variability in caffeine consumption and inconsistencies among studies linking caffeine to heart disease may be explained by genetic variation. Caffeine antagonizes adenosine receptors with downstream effects on dopamine and serotonin. The objectives of this thesis were to determine whether the DRD2 957C>T or HTR2A 102C>T polymorphisms are associated with caffeine consumption or modify the association between coffee consumption and risk of myocardial infarction (MI). DRD2 genotype was associated with caffeine consumption among non-smokers and CYP1A2 -163C allele carriers. HTR2A genotype was associated with caffeine consumption among non-smokers and subjects with the ADORA2A TT genotype. Neither polymorphism modified the association between coffee consumption and risk of MI; however, a significant coffee x HTR2A interaction was seen among subjects with the CYP1A2 -163C allele. The results suggest caffeine’s reinforcing effects may be mediated by the dopamine and serotonin receptors and implicate serotonin in caffeine’s effect on risk of MI.
Book chapters on the topic "DRD2 receptors polymorphisms"
1
Tomitaka, Shin-Ichiro. "Association Between Novelty Seeking and Dopamine Receptor D4 (DRD4) Exon III Polymorphism." In Contemporary Neuropsychiatry. Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-67897-7_72.
Full text
2
V. Gafarov, Valery, Elena A. Gromova, Vladimir N. Maksimov, Igor V. Gagulin, and Almira V. Gafarova. "Association of Personal Anxiety with Dopamine Receptor D4 (DRD4), DAT Genes Polymorphism." In Anxiety Disorders [Working Title]. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.94386.
Full textAbstract:
Modern studies in the world have attached high priority to the role of genetics in human psychosocial stress. People who have strong biochemical responses to stress are more inclined to develop acute and posttraumatic stress disorders. Why do such unusually strong biological reactions occur in certain people? Psychogenetics focuses on many aspects: personality traits that can affect human behavior directly. Their individual variability has been found to be a genetic trait. At present we already know a number of genes, certain allelic variants and genotypes associated with some neuropsychological characters. Among these are genes encoding intracellular and plasma protein neurotransmitter transporters and their receptors; to date, there are only several dozen genes. Of particular interest are dopaminergic system genes. However, information about the polymorphism of known genes associated with personality traits is quite limited and contradictory for open population. Under these circumstances, the chapter is devoted to the association of polymorphisms of candidate genes of the dopaminergic system with anxiety in the open population.